We are live on ! Find out more
EAM

Eventide Asset Management Portfolio holdings

AUM $6.05B
1-Year Est. Return 76.64%
This Fund
S&P 500
This Quarter Est. Return
-16.98%
1 Year Est. Return
+76.64%
3 Year Est. Return
+247.17%
5 Year Est. Return
+285.6%
10 Year Est. Return
+2,546.71%
AUM
$4.68B
AUM Growth
-$1.71B
Cap. Flow
-$462M
Cap. Flow %
-9.88%
Top 10 Hldgs %
25.31%
Holding
149
New
16
Increased
23
Reduced
54
Closed
13

Top Buys

Rank Stock Value
1
DOCS icon
Doximity
DOCS
+$59.6M
2
GTM
ZoomInfo Technologies
GTM
+$19.8M
3
CMS icon
CMS Energy
CMS
+$19.8M
4
GH icon
Guardant Health
GH
+$18.2M
5
LNG icon
Cheniere Energy
LNG
+$15.6M

Top Sells

Rank Stock Value
1
DT icon
Dynatrace
DT
+$112M
2
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$64.6M
3
SMAR
Smartsheet Inc.
SMAR
+$38.2M
4
ROP icon
Roper Technologies
ROP
+$32.9M
5
LRCX icon
Lam Research
LRCX
+$31.8M

Sector Composition

Rank Sector Weight
1 Healthcare 35.3%
2 Technology 26.13%
3 Industrials 16.22%
4 Consumer Discretionary 5.49%
5 Utilities 5.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
WD icon
101
Walker & Dunlop
WD
$1.68B
$9.11M 0.19%
94,535
-27,400
-22% -$3.02M
PRAX icon
102
Praxis Precision Medicines
PRAX
$8.58B
$8.62M 0.18%
234,537
-58,463
-20% -$6.24M
VCYT icon
103
Veracyte
VCYT
$4.77B
$8.32M 0.18%
418,000
– –
VITL icon
104
Vital Farms
VITL
$536M
$8.31M 0.18%
950,092
-1,239,959
-57% -$13.2M
PRVA icon
105
Privia Health
PRVA
$3.01B
$8.09M 0.17%
+277,800
New +$7.06M
EGP icon
106
EastGroup Properties
EGP
$11.3B
$7.84M 0.17%
50,800
– –
MRTX
107
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$7.59M 0.16%
113,000
-340,781
-75% -$21.7M
TRML
108
DELISTED
Tourmaline Bio
TRML
$7.04M 0.15%
156,109
– –
ROIV icon
109
Roivant Sciences
ROIV
$24.8B
$6.74M 0.14%
1,690,300
– –
EVH icon
110
Evolent Health
EVH
$358M
$6.66M 0.14%
+216,700
New +$6.31M
TRGP icon
111
Targa Resources
TRGP
$57.6B
$6.33M 0.14%
106,022
-40,678
-28% -$2.92M
OPCH icon
112
Option Care Health
OPCH
$3.36B
$6.16M 0.13%
+221,500
New +$6.3M
PLD icon
113
Prologis
PLD
$136B
$5.83M 0.12%
49,513
-117,687
-70% -$16.3M
ARE icon
114
Alexandria Real Estate Equities
ARE
$9.15B
$5.79M 0.12%
39,900
+6,200
+18% +$1.05M
HZNP
115
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$5.57M 0.12%
+69,800
New +$6.61M
XPO icon
116
XPO
XPO
$23.4B
$5.54M 0.12%
193,545
– –
GRMN
117
Garmin
GRMN
$57.4B
$5.47M 0.12%
55,700
-5,300
-9% -$558K
FRLN
118
DELISTED
Freeline Therapeutics Holdings plc American Depositary Shares
FRLN
$5.17M 0.11%
396,667
+156,254
+65% +$2.01M
SNV
119
DELISTED
Synovus
SNV
$5.12M 0.11%
142,100
-207,200
-59% -$8.57M
LOB icon
120
Live Oak Bancshares
LOB
$1.97B
$4.64M 0.1%
136,983
– –
SWAV
121
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
$4.51M 0.1%
+23,600
New +$4.17M
NARI
122
DELISTED
Inari Medical, Inc. Common Stock
NARI
$4.2M 0.09%
+61,700
New +$4.43M
INSP icon
123
Inspire Medical Systems
INSP
$1.44B
$4.18M 0.09%
+22,900
New +$4.57M
SHW icon
124
Sherwin-Williams
SHW
$83.7B
$4.14M 0.09%
18,500
– –
IONS icon
125
Ionis Pharmaceuticals
IONS
$8.81B
$4.07M 0.09%
+110,000
New +$4.15M
2 3 4
5
6

Similar funds

HPG
Harvest Portfolios Group Oakville, Ontario, Canada $6.06B AUM 16.63% 1-Year Est. Return
EMPI
Elo Mutual Pension Insurance Espoo, Finland $6.06B AUM 24.33% 1-Year Est. Return
RCG
Ruane, Cunniff & Goldfarb New York $6.03B AUM 12.06% 1-Year Est. Return
JWBC
John W. Bristol & Co New York $6.08B AUM 16.51% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
CM
CastleKnight Management New York $6B AUM 121.87% 1-Year Est. Return
CIS
Capital International Sarl Los Angeles, California $6.11B AUM 32.29% 1-Year Est. Return

Eventide Asset Management's Q2 2022 Portfolio in Review

As of Q2 2022, Eventide Asset Management held 149 positions worth $4.68B, down 27% from $6.38B the previous quarter. Its ten largest holdings account for 25% of the portfolio.

Eventide Asset Management withdrew a net $462M in Q2 2022, closing 13 positions and reducing 54 holdings. Its most notable exit was Dynatrace, an estimated $112M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 35% of assets, up from 33% a quarter earlier, followed by Technology and Industrials.

Against the trend, Eventide Asset Management opened a new position in Doximity worth $52.7M.

  • Eventide Asset Management's largest Q2 2022 buy was Doximity: 1,512,602 shares worth $52.7M.
  • Eventide Asset Management added most to ZoomInfo Technologies in Q2 2022, an estimated $19.8M increase.
  • Eventide Asset Management's biggest Q2 2022 reduction was Biohaven Pharmaceutical Holding Company Ltd., cutting an estimated $64.6M.
  • Eventide Asset Management fully exited Dynatrace in Q2 2022, selling an estimated $112M.
  • Eventide Asset Management's ten largest holdings make up 25% of its $4.68B portfolio in Q2 2022.
  • Eventide Asset Management opened 16 new positions and closed 13 in Q2 2022.
  • Eventide Asset Management's portfolio value fell 27% quarter-over-quarter to $4.68B.

Based on Eventide Asset Management's 13F filing for Q2 2022, filed 15 Aug 2022.